Cargando…

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation

Osteolytic bone disease is a hallmark of multiple myeloma (MM). A significant fraction (~20%) of MM patients do not develop osteolytic lesions (OLs). The molecular basis for the absence of bone disease in MM is not understood. We combined PET-CT and gene expression profiling (GEP) of purified BM CD1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gai, Dongzheng, Chen, Jin-Ran, Stewart, James P., Nookaew, Intawat, Habelhah, Hasem, Ashby, Cody, Sun, Fumou, Cheng, Yan, Li, Can, Xu, Hongwei, Peng, Bailu, Garg, Tarun K., Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Chen, Fangping, Barlogie, Bart, van Rhee, Frits, Tricot, Guido, Shaughnessy, John D., Zhan, Fenghuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479617/ https://www.ncbi.nlm.nih.gov/pubmed/35881476 http://dx.doi.org/10.1172/JCI159527

Ejemplares similares

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma
por: Al Hadidi, Samer, et al.
Publicado: (2023)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States
por: Al Hadidi, Samer, et al.
Publicado: (2022)

3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns
por: Schinke, Carolina, et al.
Publicado: (2019)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Nasopharyngeal amyloidoma with osteolytic lesions leading to diagnosis of systemic light‐chain amyloidosis
por: Susanibar‐Adaniya, Sandra, et al.
Publicado: (2017)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2022)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
por: Ling, Wen, et al.
Publicado: (2023)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
por: Schinke, Carolina, et al.
Publicado: (2020)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
por: Larsen, Kristin, et al.
Publicado: (2022)

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
por: Baker, David, et al.
Publicado: (2021)

TRAF2 phosphorylation promotes NF-κB–dependent gene expression and inhibits oxidative stress-induced cell death
por: Zhang, Laiqun, et al.
Publicado: (2011)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
por: Davies, Faith E., et al.
Publicado: (2018)

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
por: Rasche, Leo, et al.
Publicado: (2019)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant
por: Mathur, Pankaj, et al.
Publicado: (2017)

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
por: Hao, M, et al.
Publicado: (2017)

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
por: Li, Can, et al.
Publicado: (2021)

Bone Microenvironment‐Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice
por: Arellano, Danna L., et al.
Publicado: (2022)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

MicroRNAs and Osteolytic Bone Metastasis: The Roles of MicroRNAs in Tumor-Induced Osteoclast Differentiation
por: Kagiya, Tadayoshi
Publicado: (2015)

The structure of the CstF-77 homodimer provides insights into CstF assembly
por: Legrand, Pierre, et al.
Publicado: (2007)

Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
por: Mikulasova, Aneta, et al.
Publicado: (2022)

In vitro osteolytic activity of human myeloma plasma cells and the clinical evaluation of myeloma osteoclastic bone lesions.
por: Rossi, J. F., et al.
Publicado: (1984)

Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer
por: Liu, Jin, et al.
Publicado: (2017)

Severe Right-Sided Heart Failure and Pulmonary Hypertension with Carfilzomib Treatment in Multiple Myeloma
por: Mathur, Pankaj, et al.
Publicado: (2020)

Interactions of CstF-64, CstF-77, and symplekin: Implications on localisation and function
por: Ruepp, Marc-David, et al.
Publicado: (2011)

Maintenance Cognitive Stimulation Therapy (CST) for dementia: A single-blind, multi-centre, randomized controlled trial of Maintenance CST vs. CST for dementia
por: Aguirre, Elisa, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_dvbirbppsfvmgfot9jj148fi6t